RxDoctor Payments Data

Samantha Rubin

Nurse Practitioner · Morgantown, WVNPI 1932830163

Payments from drug & device makers

$865in general payments, 2019–2025

Across 39 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Xeris Pharmaceuticals, Inc.$154
  • Cequr Corporation$125
  • Novo Nordisk$114
  • Lilly USA, LLC$76
  • Insulet Corporation$66
  • Eisai Inc.$55
  • plus $275 from 12 others

What the payments were for

  • Food & beverage$865100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$865 in reported general payments places this provider in the 75th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$12,547
Medicare patients
76
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide59$66,631
TrulicityDulaglutide51$51,670
JardianceEmpagliflozin32$29,249
Humulin R U-500 KwikpenInsulin Regular, Human11$24,971
OzempicSemaglutide24$24,230
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/716$12,847
FarxigaDapagliflozin Propanediol17$10,882
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$4,835
Insulin Lispro Kwikpen U-100Insulin Lispro11$4,389
Levothyroxine Sodium47$3,043
Novolog FlexpenInsulin Aspart13$2,254
SynthroidLevothyroxine Sodium11$1,156
Metformin Hcl ErMetformin Hcl39$437
Metformin Hcl38$231
Pioglitazone Hcl13$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$76$118,301110 claims
Novo NordiskOzempic$114$24,23024 claims
AstraZenecaFarxiga$16$10,88217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →